Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;20(3):158-172.
doi: 10.1038/s41577-019-0232-6. Epub 2019 Dec 6.

Treg cell-based therapies: challenges and perspectives

Caroline Raffin #  1 , Linda T Vo #  1 , Jeffrey A Bluestone  2
Affiliations
Review

Treg cell-based therapies: challenges and perspectives

Caroline Raffin et al. Nat Rev Immunol. 2020 Mar.

Abstract

Cellular therapies using regulatory T (Treg) cells are currently undergoing clinical trials for the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In this Review, we discuss the biology of Treg cells and describe new efforts in Treg cell engineering to enhance specificity, stability, functional activity and delivery. Finally, we envision that the success of Treg cell therapy in autoimmunity and transplantation will encourage the clinical use of adoptive Treg cell therapy for non-immune diseases, such as neurological disorders and tissue repair.

PubMed Disclaimer

Conflict of interest statement

Competing interests

J.A.B. is a stock holder and member of the Board of Directors on Rheos Medicines; a stock holder and member of the Board of Directors for Provention Bio; and a stock holder and member of the Scientific Advisory Boards of Vir Therapeutics, Arcus Biotherapeutics, Quentis Therapeutics, Solid Biosciences and Celsius Therapeutics (Founder). J.A.B. owns stock in MacroGenics Inc., Vir Therapeutics, Arcus Biotherapeutics, Quentis Therapeutics, Solid Biosciences and Celsius Therapeutics. C.R. and L.T.V. declare no competing interests. J.A.B is the President and CEO of a newly formed biotech company targeting Treg therapy for the treatment of autoimmune and other immune disorders.

Figures

Fig. 1 |
Fig. 1 |. Mechanisms of action of effector T cells versus Treg cells.
a | The recognition of specific antigens presented or cross-presented by antigen-presenting cells (APCs) activates CD4+ and CD8+ T cells, respectively. Following activation, CD4+ T cells produce cytokines that help CD8+ T cells to differentiate into cytotoxic T lymphocytes (CTLs). CTLs then kill target cells by performing their cytotoxic activity in an antigen-specific and cell contact-dependent manner. b | Like effector T cells, regulatory T (Treg) cell activation is antigen specific. However, once activated, Treg cells exert bystander suppression, meaning that they have suppressive function regardless of their antigen specificity. Treg cells suppress effector T cells using direct or indirect mechanisms of action. Finally, Treg cells can spread their suppressive properties to neighbouring cells via a phenomenon named infectious tolerance. IDO, indoleamine-2,3-dioxygenase; IFNγ, interferon-γ; MHC, major histocompatibility complex; TCR, T cell receptor; TGFβ, transforming growth factor-β.
Fig. 2 |
Fig. 2 |. Various Treg cell products for Treg cell-based therapy.
There are currently three main regulatory T (Treg) cell products developed for adoptive cell therapy (ACT). a | The most widely used product in clinical trials is expanded polyclonal Treg cells that were isolated from peripheral blood and expanded in vitro using high-dose IL-2 and anti-CD3/CD28 beads to generate a high number of Treg cells for ACT. b | Another approach, mainly used in transplantation to prevent graft rejection, is the use of antigen-presenting cells (APCs) from the graft donor to specifically stimulate alloreactive Treg cells from the recipient in vitro. These antigen-specific Treg cells have been proven to be more potent than polyclonal Treg cells. However, the cell yield is relatively low after expansion, and this approach cannot be adapted for the treatment of autoimmune diseases owing to the low precursor frequencies of specific autoantigen-reactive Treg cells. c | A third approach is the expansion of polyclonal Treg cells genetically engineered to express a synthetic receptor (chimeric antigen receptor (CAR) or artificial T cell receptor (TCR)) that recognizes a target antigen of interest. With this strategy, a high number of antigen-specific Treg cells can be obtained after expansion.
Fig. 3 |
Fig. 3 |. Characteristics of recombinant T cell receptors versus chimeric antigen receptors.
T cell receptors (TCRs) are commonly composed of a heterodimer of one α-chain and one β-chain that can bind to a specific peptide–major histocompatibility complex (MHC) and subsequently activate the CD3 complex that is made of four signalling subunits: one dimer of CD3ε and CD3γ chains, one dimer of CD3ε and CD3δ chains, and one homodimer of CD3ζ chains. Recombinant TCRs are generated through the integration of the genes that encode for the α- and β-chains of a TCR specific for an antigen of interest. Second-generation chimeric antigen receptors (CARs) are artificial immunoreceptors composed in their extracellular part of a single-chain variable fragment (scFv) capable of binding a target antigen that is linked to a transmembrane domain via a hinge and in their intracellular part of a co-stimulatory domain (CD28 or 4–1BB) and a CD3ζ domain that together effectively trigger the activation of the CAR-expressing T cell after binding of the antigen. ACT, adoptive cell therapy; CRS, cytokine release syndrome; ECM, extracellular matrix; Treg cell, regulatory T cell.
Fig. 4 |
Fig. 4 |. The future of Treg cell-based therapy.
Universal donor regulatory T (Treg) cells for adoptive cell therapy represent the ultimate goal to broaden the use of Treg cells as therapeutics. Recent advances in genome editing and ongoing studies aimed at differentiating various T cell subsets from induced pluripotent stem (iPS) cells have the potential to enable the generation of Treg cells compatible with any major histocompatibility complex (MHC) class and equipped with an adjustable immunoreceptor to confer the appropriate antigen specificity based on patient needs. Treg cells will be isolated from a healthy donor (from peripheral blood (PB) or umbilical cord blood (UCB)) or differentiated from iPS cells, which can be derived from fibroblasts. Treg cells will be expanded in vitro and subjected to genome editing using a non-viral approach, such as CRISPR–Cas9 technology, to equip the cells with a synthetic immunoreceptor and other payloads such as an orthogonal IL-2/IL-2 receptor (IL-2R) pair. a | By knocking out the donor HLA molecules and knocking in a non-classical HLA, Treg cells can be made compatible with any HLA profile while being protected from natural killer cell-mediated cytotoxicity. Moreover, based on recent effector T cell studies, we envision that replacing the endogenous T cell receptor (TCR) with a synthetic immunoreceptor will confer the desired antigen specificity to Treg cells to improve their potency while removing the endogenous TCR to prevent mispairing. In addition, the potency of the engineered Treg cells will be optimized by equipping them with neomorphic properties, such as the expression of chemokine receptors to enhance their migration to the target tissue, the production of immunosuppressive cytokines to improve their suppressive activity as well as the expression of the orthogonal pair of IL-2/IL-2 receptor (IL-2R) to promote their specific survival. Importantly, technologies, such as the Synthetic Notch (SynNotch) system, may be used to control the expression and activity of these neomorphic properties. Finally, in case of an adverse event (for example, cell instability, off-target toxicity), engineered Treg cells will express a suicide cassette to allow efficient and rapid elimination if necessary. b | Although most of the effort in the Treg cell field to redirect the cell antigen specificity has been made using classic chimeric antigen receptors (CARs) or TCRs, the ideal engineered immunoreceptor should be universal with an adjustable antigen recognition domain (that is, the antigen recognition domain should be separated from the signalling domain of a conventional CAR, enabling one to pick and even switch the antigen specificity of the cells). To this aim, alternative approaches, such as by Xyphos Biosciences (convertible CAR), Unum Therapeutics (ACTR, antibody-coupled TCR) and CALIBR (switchable CAR), focus on the development of universal binding sites for antigen receptors to redirect tissue targeting. Although these approaches have been developed for effector T cells, they could also be translated to Treg cell engineering to direct the cells to specific sites of inflammation using universal binding platforms. Similar to CARs, engineered TCRs are capable of redirecting the antigen specificity of Treg cells, and novel TCR-based technologies are being evaluated. Notably, TCR2 Therapeutics has designed a T Cell Receptor Fusion Construct (TRuC) platform that consists of the fusion of a single-chain variable fragment (scFv) specific for a surface antigen of interest to the extracellular N termini of one of the TCR subunits, which enables the recognition of the antigen on target cells without the need for HLA presentation and engages the complete TCR machinery. MicAbody, modified MHC-class I-related chain A fused to an antibody; iNKG2D, inert natural killer group 2, member D receptor; PNE, peptide neo-epitope.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Edinger M et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med 9, 1144–1150 (2003). - PubMed
    1. Cohen JL, Trenado A, Vasey D, Klatzmann D & Salomon BL CD4+CD25+ immunoregulatory T cells: new therapeutics for graft-versus-host disease. J. Exp. Med 196, 401–406 (2002). - PMC - PubMed
    1. Taylor PA, Lees CJ & Blazar BR The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99, 3493–3499 (2002). - PubMed
    1. Xia G, He J & Leventhal JR Ex vivo-expanded natural CD4+CD25+ regulatory T cells synergize with host T-cell depletion to promote long-term survival of allografts. Am. J. Transpl 8, 298–306 (2008). - PubMed
    1. Xiao F et al. Ex vivo expanded human regulatory T cells delay islet allograft rejection via inhibiting islet-derived monocyte chemoattractant protein-1 production in CD34+ stem cells-reconstituted NOD-scid IL2rγnull mice. PLOS ONE 9, e90387 (2014). - PMC - PubMed

MeSH terms